CRESCENT-HEALTHCARE
13.3.2023 15:28:44 CET | Business Wire | Press release
The US Society of Robotic Surgery and Crescent Healthcare (a Division of the Crescent Group of Companies) host the first Global Robotic MedTech Forum in the Middle East on 16 March 2023 in Dubai. The event, the first dedicated global forum to gather world renowned experts in the region, will focus on the latest advancements in robotic surgery, a rapidly growing field that is revolutionizing healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005505/en/
His Excellency AbdulRahman bin Mohamed Al Owais, UAE Minister of Health and Prevention (Photo: AETOSWire)
The Forum will host ministers, senior government officials, as well as healthcare, R&D and investment professionals to discuss the future of robotic assisted surgery, in addition to the UAE’s leading position at the cutting-edge of healthcare.
His Excellency AbdulRahman bin Mohamed Al Owais, UAE Minister of Health and Prevention, commented: "As we navigate the challenges of modern healthcare, the UAE is proud to host the Global Robotic MedTech Forum. By embracing technology and innovation, we can further improve patient outcomes and provide more efficient and effective healthcare solutions for all."
Dr. Vipul Patel, President, Society of Robotic Surgery, and one of the world's most experienced robotic surgeons said: "The Forum will provide a unique platform for knowledge exchange and explore innovative solutions that can vastly help improve patient outcomes."
Mr. Hamid Jafar, Chairman of the Crescent Group of Companies, which is hosting the event, said: "The Global Robotic MedTech Forum is an important platform that brings together industry leaders to drive meaningful advancements in the healthcare sector. We are pleased to host this event and look forward to enabling the sharing of insights and knowledge in this exciting field."
Dr. Fred Moll, Founder of Intuitive Surgical and a pioneer of robotic surgery, said: "Honored to be part of the Forum and have the opportunity to share insights on the future of robotic surgery with fellow innovators and industry leaders."
Neeraj Agrawal, Board Member of EndoQuest, said: "This event brings together the best and brightest global minds in the field to the Gulf region, and we are honored to participate."
Kurt Azarbarzin, CEO of EndoQuest, added: "We are excited to present the latest innovations in scarless incisionless robotic surgery deploying flexible robots through natural human orifices."
Eduardo Fonseca, Board Member of XCath, commented: “From advanced imaging and sensors to cutting-edge robotics and AI, the possibilities for enhancing patient outcomes and improving the quality of care are endless. The Gulf region will be at the forefront of the development of groundbreaking technologies that have the potential to transform the healthcare industry."
The Global Robotic MedTech Forum will feature some of the most prominent global figures in the field of robotic surgery including Dr. Chris Thompson, Professor at Harvard University who has been at the forefront of developing and testing new robotic surgical techniques. Dr. Santiago Horgan, the Director of UC San Diego’s Center for the Future of Surgery will also share his insights. The participation of these distinguished experts underscores the importance of the Global Robotic MedTech Forum as a platform for sharing knowledge and advancing the field of robotic medicine.
The Forum will feature keynote speeches from leading experts in the field, interactive panel discussions, and hands-on demonstrations of the latest robotic surgical systems. Attendees will have the opportunity to learn about the latest advancements in the field, and to see first-hand how robotic surgery is rapidly changing the face of healthcare globally.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005505/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom